PL4426270T3 - Nanocząsteczki lipidowe do dostarczania oligonukleotydów - Google Patents
Nanocząsteczki lipidowe do dostarczania oligonukleotydówInfo
- Publication number
- PL4426270T3 PL4426270T3 PL22813505.9T PL22813505T PL4426270T3 PL 4426270 T3 PL4426270 T3 PL 4426270T3 PL 22813505 T PL22813505 T PL 22813505T PL 4426270 T3 PL4426270 T3 PL 4426270T3
- Authority
- PL
- Poland
- Prior art keywords
- lipid nanoparticles
- oligonucleotide delivery
- oligonucleotide
- delivery
- nanoparticles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205904 | 2021-11-02 | ||
| EP22179399 | 2022-06-16 | ||
| PCT/EP2022/080581 WO2023078950A1 (en) | 2021-11-02 | 2022-11-02 | Lipid nanoparticles for oligonucleotide delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4426270T3 true PL4426270T3 (pl) | 2025-11-24 |
Family
ID=84364268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22813505.9T PL4426270T3 (pl) | 2021-11-02 | 2022-11-02 | Nanocząsteczki lipidowe do dostarczania oligonukleotydów |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250236599A1 (https=) |
| EP (2) | EP4613741A3 (https=) |
| JP (1) | JP2024540108A (https=) |
| KR (1) | KR20240099377A (https=) |
| AU (1) | AU2022381463A1 (https=) |
| CA (1) | CA3236653A1 (https=) |
| DK (1) | DK4426270T3 (https=) |
| ES (1) | ES3042660T3 (https=) |
| FI (1) | FI4426270T3 (https=) |
| IL (1) | IL312432B1 (https=) |
| MX (1) | MX2024005109A (https=) |
| PL (1) | PL4426270T3 (https=) |
| WO (1) | WO2023078950A1 (https=) |
| ZA (1) | ZA202403360B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| CN118125994A (zh) * | 2022-11-25 | 2024-06-04 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
| WO2024136309A1 (en) * | 2022-12-23 | 2024-06-27 | Green Cross Corporation | Ionizable lipid and use thereof |
| CN116514696B (zh) * | 2023-06-29 | 2023-12-01 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| WO2025104023A1 (en) | 2023-11-13 | 2025-05-22 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025128696A1 (en) * | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025255534A1 (en) * | 2024-06-07 | 2025-12-11 | Innovac Therapeutics Hk Limited | Diol-based novel ionizable lipids and their uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CN1989250B (zh) | 2004-05-18 | 2013-11-20 | 阿尔法瓦克斯公司 | Tc-83衍生的甲病毒属载体、颗粒和方法 |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| WO2014028487A1 (en) * | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| WO2018232120A1 (en) * | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
-
2022
- 2022-11-02 PL PL22813505.9T patent/PL4426270T3/pl unknown
- 2022-11-02 JP JP2024525411A patent/JP2024540108A/ja active Pending
- 2022-11-02 DK DK22813505.9T patent/DK4426270T3/da active
- 2022-11-02 WO PCT/EP2022/080581 patent/WO2023078950A1/en not_active Ceased
- 2022-11-02 FI FIEP22813505.9T patent/FI4426270T3/fi active
- 2022-11-02 ES ES22813505T patent/ES3042660T3/es active Active
- 2022-11-02 MX MX2024005109A patent/MX2024005109A/es unknown
- 2022-11-02 CA CA3236653A patent/CA3236653A1/en active Pending
- 2022-11-02 IL IL312432A patent/IL312432B1/en unknown
- 2022-11-02 EP EP25189933.2A patent/EP4613741A3/en active Pending
- 2022-11-02 AU AU2022381463A patent/AU2022381463A1/en active Pending
- 2022-11-02 EP EP22813505.9A patent/EP4426270B1/en active Active
- 2022-11-02 KR KR1020247018058A patent/KR20240099377A/ko active Pending
- 2022-11-02 US US18/705,479 patent/US20250236599A1/en active Pending
-
2024
- 2024-04-30 ZA ZA2024/03360A patent/ZA202403360B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4613741A2 (en) | 2025-09-10 |
| EP4426270B1 (en) | 2025-07-23 |
| US20250236599A1 (en) | 2025-07-24 |
| IL312432B1 (en) | 2026-01-01 |
| EP4426270A1 (en) | 2024-09-11 |
| JP2024540108A (ja) | 2024-10-31 |
| MX2024005109A (es) | 2024-05-31 |
| KR20240099377A (ko) | 2024-06-28 |
| WO2023078950A1 (en) | 2023-05-11 |
| IL312432A (en) | 2024-06-01 |
| ES3042660T3 (en) | 2025-11-24 |
| FI4426270T3 (fi) | 2025-09-12 |
| DK4426270T3 (da) | 2025-09-22 |
| AU2022381463A1 (en) | 2024-05-16 |
| EP4613741A3 (en) | 2025-11-12 |
| ZA202403360B (en) | 2025-08-27 |
| CA3236653A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312432A (en) | Lipid nanoparticles for delivery of oligonucleotides | |
| PL4426269T3 (pl) | Nanocząstki lipidowe do dostarczania oligonukleotydów | |
| GB2600859B (en) | Improved lipid nanoparticles for delivery of nucleic acids | |
| IL290592A (en) | A cationic lipid that can be ionized for the administration of RNA | |
| EP2792367A4 (en) | LIPID NANOPARTICLES FOR A DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS | |
| IL299787A (en) | Cationic lipids for use in lipid nanoparticles | |
| EP4346781A4 (en) | DNA VECTOR DELIVERY USING LIPID NANOPARTICLES | |
| IL304759A (en) | Lipids suitable for the transfer of nucleic acids | |
| AU2016202433A1 (en) | Novel low molecular weight cationic lipids for oligonucleotide delivery | |
| IL245638B (en) | A cationic lipid that undergoes ionization for DNA delivery | |
| IL252291B (en) | A cationic lipid that undergoes ionization to provide RNA | |
| EP3399038A3 (en) | Oligonucleotide analogues targeting human lmna | |
| ES3063637T3 (en) | Lipid nanoparticle compositions and methods for mrna delivery | |
| EP2694130A4 (en) | VARIABLE LENGTH CATHETER FOR DRUG DELIVERY | |
| EP2364085A4 (en) | CATIONIC RELEASABLE LIPIDS FOR NUCLEIC ACID DELIVERY SYSTEMS | |
| EP2885045A4 (en) | METHOD FOR MANUFACTURING DRUG DELIVERY FORMULATIONS | |
| CA3266203A1 (en) | LIPID NANOPARTICLE FORMULATIONS FOR ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES | |
| IL246378A0 (en) | A hybrid matrix of polymers that adhere to the mucosa and a lipidic drug release system for the treatment of oral cancer | |
| EP2670780A1 (en) | Cellulose-based nanoparticles for drug delivery | |
| PT4426270T (pt) | Nanopartículas lipídicas para distribuição de oligonucleótidos | |
| GB201110632D0 (en) | Drug delivery formulations | |
| ZA202301633B (en) | Solid lipid nanoparticles for targetted drug delivery | |
| GB202316478D0 (en) | Lipid nanoparticles | |
| GB202411975D0 (en) | Nanoparticles for extended release drug delivery |